ArticleFrontiers in oncology2022

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report.

Tsukasa Yoshida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.